Oliver A. Cornely

TL;DR: Echinocandins have a favourable tolerability profile and exhibit a minimal potential for drug interactions since their pharmacokinetics is independent of renal and hepatic function, and are appropriate drugs of choice for invasive candidiasis in intensive care where many patients experience organ failure and receive multiple drugs with complex interactions.

TL;DR: Pharmacokinetic modeling suggests that intravenous TID dosing at 9 mg/kg per dose for up to 3 days may result in a substantially higher percentage of children 2 to 12 years of age with adequate exposure to VCZ early during treatment.

TL;DR: Mucormycosis Francisco M. Marty; John R. Perfect; Oliver A. Cornely; Kathleen M. Mullane; Galia Rahav; Misun Lee; Masanori Ito; Rochelle Maher; Bernhardt Zeiher; Luis Ostrosky-Zeichner; Brigham and Women’s Hospital Boston, MA; Duke University, Durham, NC.

TL;DR: Candidemia is among the most frequent nosocomial bloodstream infections and case‐control studies on amphotericin B and fluconazole estimated attributable mortality rates may have decreased after introduction of echinocandins.

TL;DR: Risk factors, antiviral treatment and outcomes of SARS-CoV-2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry are described.